Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, will be
releasing its Fiscal 2019 Second Quarter financial results on Tuesday
May 28th, 2019, after markets close. A conference call to
discuss the financial results will be held Wednesday May 29th,
2019, at 9:00am EST. To participate in the conference call, please dial:
Toll-Free: 833.299.8117
International: 647.689.4535
Conference
ID Code: 1599884
A recording of the call will be available by calling 855.859.2056 or
404.537.3406 and entering the conference ID code 1599884 from May 29th,
2019, at 12:00pm EST to June 12th, 2019, at 11:59pm EST. A
recording of the call will also be available on www.covalon.com
on the Investor page under Events Calendar.
Copies of Covalon’s financial statements and MD&A can be obtained on
SEDAR at www.sedar.com,
as well as the Investor Relations tab of the Company’s website at www.covalon.com.
About Covalon
Covalon Technologies Ltd. researches,
develops, and commercializes new healthcare technologies that help save
lives around the world. Covalon's patented technologies, products, and
services address the advanced healthcare needs of medical device
companies, healthcare providers, and individual consumers. Covalon's
technologies are used to prevent, detect, and manage medical conditions
in specialty areas such as infection control, vascular access, surgical
procedures, advanced wound care, and medical device coatings. To learn
more about Covalon, visit our website at www.covalon.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect
the Company's current expectations regarding future events. The
forward-looking statements are often, but not always, identified by the
use of words such as "seek", "anticipate", "plan, "estimate", "expect",
"intend" and statements that an event or result "may", "will", "should",
"could" or "might" occur or be achieved and other similar expressions.
These forward-looking statements involve risk and uncertainties,
including completion of integration of the AquaGuard acquisition, the
difficulty in predicting product approvals, acceptance of and demands
for new products, the impact of the products and pricing strategies of
competitors, delays in developing and launching new products, the
regulatory environment, fluctuations in operating results and other
risks, any of which could cause results, performance, or achievements to
differ materially from the results discussed or implied in the
forward-looking statements. Many risks are inherent in the industry;
others are more specific to the Company. Investors should consult the
Company's ongoing quarterly filings for additional information on risks
and uncertainties relating to these forward-looking statements.
Investors should not place undue reliance on any forward-looking
statements. The Company assumes no obligation to update or alter any
forward-looking statements whether as a result of new information,
further events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190527005200/en/
Copyright Business Wire 2019